Revisiting Outcomes-Based Pricing Propositions for the PCSK9 Inhibitor Evolocumab
The approval of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab was based on the 61% reduction in the surrogate outcome of low-density lipoprotein cholesterol shown in clinical trials, 1 which, based on the lowdensity lipoprotein hypothesis, was expected to translate into a 36% to 39% reduction in the risk of cardiovascular events. cacy of evolocumab in preventing cardiovascular events, were recently published. In the FOURIER trial, 5 evolocumab was associated with a 27% and 21% reduction in the risk of myocardial infarction (MI) and stroke, respectively. There was no reduction in cardiovascular death or all-cause mortality. Following the publication of these results, which failed to meet the expectations generated by previous predictions, 2 Amgen announced its willingness to engage in contracts where the cost of evolocumab would be refunded for patients who have an MI or a stroke while using the drug. In this article, I simulate the annual price of evolocumab under the outcome-based contracts proposed by Amgen, and put my estimates in the context of the available evidence on the cost-effectiveness of PCSK9 inhibitors.
Methods | To conduct this analysis, I used an estimate recently released by Amgen of the standard industry discounts for evolocumab. 6 To estimate outcomes-based refunds, I simulated the number of patients that would qualify for outcomes-based refunds based on the rates of MI and stroke derived from the FOURIER trial. 5 I computed these calculations for 2 scenarios:
(1) assuming refunds would equal lifetime evolocumab expenditures; and (2) assuming refunds would be limited to a maximum of 3 years of evolocumab therapy. Finally, I calculated the cost of averting an MI and a stroke as the product of the annual price of evolocumab after the application of standard industry discounts and outcomes-based refunds, as well as the number needed to treat estimated from the FOURIER trial. "We hope you don't believe your doctor when they tell you there is nothing they can do, you were smart to call us."
"It takes years to determine the effect or outcome of the procedure."
"[Adverse effects] are typically good, we had a patient come in for diabetes and treatment caused his bleeding hemorrhoids to stop."
"Problem areas act as a magnet to stem cells."
"It is hard for me to know how many cells are actually getting where they need to go."
"If you have a million dollars to spend we will set you up with weekly infusions."
Results | After the application of standard industry discounts, which average 30% to 35% for evolocumab, 6 the annual price of evolocumab is $9100 (65% of $14 000). If the contracts announced by Amgen were applied to a population comparable to the FOURIER trial 5 sample, payers would be refunded the cost of evolocumab in 2.15% of the patients. This would be equivalent to the application of a 2.15% price reduction across patients, which would translate into an annual price of $8904 ( Figure [Scenario 1] ). These estimates are, however, too optimistic because they assume the manufacturer would refund lifetime expenditures in PCSK9 inhibitors. More likely, refunds would be limited to just a few years of therapy. For instance, if refunds were limited to 3 years of therapy, the average annual price of evolocumab would be $9061 ( Figure [Scenario 2] ). This scenario is also more realistic because, with the high turnover characteristic of the insurance market, payers would unlikely get refunds for patients who switch plans. Under these conditions, it would take $1.6 million to prevent a single MI and $4.9 million to avert a single stroke. 5 Putting these estimates into the cost-effectiveness context is challenging because the FOURIER trial 5 did not directly measure quality-adjusted life years and because previous cost-effectiveness studies 2, 3 assumed evolocumab would be associated with a greater reduction in the risk of cardiovascular events than the FOURIER trial found. Even if the results from these studies 2,3 are too favorable, my estimates for the annual price of evolocumab after discounts and outcomes-based refunds double the prices at which these studies predicted evolocumab would be cost effective ($4250-$4500).
2,3
Discussion | As payers consider engaging in outcomes-based contracts for pharmaceuticals, they will have to negotiate whether these contracts will be applied in lieu of current discounts or as a complement. For outcomes-based contracts to replace current discounts, manufacturers will have to bear an amount of risk that is at least financially comparable to current discounts. Additionally, payers will have to make sure outcomes-based contracts capture the evidence available on the value of the therapy under negotiation. Otherwise, there is a risk that outcomes-based contracts will become the latest complicated artifact used in the reimbursement of pharmaceuticals without providing any additional value to the current mechanisms.
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Figure. Estimated Annual Price of Evolocumab After the Application of Standard Industry Discounts and Outcomes-Based Refunds
Annual price of evolocumab = $14 000
Standard discounts of 30% to 35% = $4200 to $4900
Annual price after discounts = $9100
Outcomes-based refunds for patients experiencing an MI or a stroke (2.15%) a MI indicates myocardial infarction; NNT, number needed to treat. a If outcomes-based contracts were applied to a population comparable to the FOURIER sample, payers would be refunded the cost of evolocumab in 2.15% of the patients treated (estimate from the FOURIER trial for the combined risk of MI and stroke in the evolocumab group at 12 months follow-up). Women, the elderly, and minorities have been underrepresented in clinical trials. 1-3 Risks and benefits of medical therapies, however, can vary based on these patient characteristics. The 2012 Food & Drug Administration (FDA) Safety and Innovation Act sought to address this issue by requiring the agency to initiate a plan that increases enrollment and clinical data for these important patient groups. This requirement led to the 2014 FDA Action Plan. 4 We characterized enrollment reporting and evaluation of device safety and effectiveness for women, the elderly, and minorities for all 2015 premarket approval (PMA) devices, which undergo the most rigorous FDA review.
Methods | For each original PMA device approved in 2015, we abstracted data on the number of patients enrolled according to age, race, and/or ethnicity, and sex for all studies, both nonpivotal and pivotal, from both the Summary of Safety and Effectiveness Data ("Summary") and device labels. We also determined whether results were analyzed by age, race and/or ethnicity, and sex; and if so, whether any difference in device safety or effectiveness was identified, even if a statistical analysis was not reported. We collected additional details for sex because the FDA issued a specific 1994 directive calling for analysis of gender bias in assessment of PMA devices. 5 We used descriptive statistics to analyze the data.
Results | In 2015, 82 studies supported FDA approval of 42 original PMA devices. Of the 82 studies, age was reported for 53 (65%) in FDA Summaries and 41 (50%) in device labels (Table 1) ; race and/or ethnicity was reported for 42 (51%) and 27 (33%), respectively; and of 77 studies including both men and women, sex composition was reported for 51 (66%) and 38 (49%), respectively. However, there was a discrepancy between the number of people enrolled and the number for which mean age was reported for 17 (32%) of 53 studies. A discrepancy also was found for reporting race and/or ethnicity in 17 (41%) of 41 studies, and for sex composition in 17 (33%) of 51 studies. Seventeen studies (21%) had an upper age limit, ranging from 50 to 85 years. 
